Nebenwirkungen · Braftovi
Braftovi 50 mg hard capsules Braftovi 75 mg hard capsules · Abschnitt 4.8 · PDF-Seite 19
HOS-140103 · Präparat HOS-098444
Colorectal cancer Encorafenib and cetuximab combination In patients treated with encorafenib 300 mg in combination with cetuximab, rash occurred in 30.6% (66/216) of patients. Most events were mild, with Grade 3 event reported in 0.5% (1/216) of patients. Rash led to dose interruption in 0.5% (1/216) of patients. Encorafenib with cetuximab and FOLFOX combination In the pooled EC+FOLFOX population, rash occurred in 35.9% (93/259) of patients. Most events were mild, with Grade 3 event reported in 1.2% (3/259) of patients. Rash led to treatment discontinuation in 0.8% (2/259) of patients and led to dose interruption or reduction in 4.2% (11/259) of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T15:53:00Z · SHA-256 47125c84bb304df39202c4dc14aefc287bbf903ef279d3e55fe42dc6648e375c · Passage 0d5ff3b4916956bec3f8159d286759124941f1adfda5f6c7ae56d76daa152ab7 · Zeichen 23553–24216 im Abschnitt